Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1409012/000119312509169181/d10q.htm
October 2010
July 2010
June 2010
May 2010
March 2010
February 2010
January 2010
December 2009
November 2009
August 2009
Exhibit 99.1
News Release |
11755 Wilshire Blvd., 20th Floor Los Angeles, CA 90025 |
ABRAXIS BIOSCIENCE REPORTS 2009 SECOND QUARTER
FINANCIAL RESULTS
Second Quarter Highlights:
| ABRAXANE® Revenue Grows to $75 Million, Representing a 6 Percent Sequential Quarterly Increase |
| Company Reports Net Loss for Common Shareholders of $23 Million, or $0.58 Per Share, or Adjusted Net Loss for Common Shareholders of $10 Million, or $0.25 Per Share |
LOS ANGELES, Calif. August 6, 2009 Abraxis BioScience, Inc. (NASDAQ: ABII), a fully integrated biotechnology company, today reported unaudited financial results for the second quarter ended June 30, 2009.
As of January 2, 2009, the company re-acquired the exclusive rights to market ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in the U.S. As a result, beginning in 2009, the company no longer recognizes deferred revenue related to the original co-promotion agreement.
Net revenue for the second quarter of 2009 was $85.1 million compared with $77.6 million for the second quarter of 2008. Revenue from sales of ABRAXANE for the second quarter of 2009 was $75.2 million compared with $73.8 million for the same period in 2008, which included recognition of deferred revenue of $9.1 million related to the co-promotion agreement. Excluding the recognition of deferred revenue, total revenue from sales of ABRAXANE for the second quarter of 2009 grew 16 percent to $75.2 million compared with $64.7 million for the same period in 2008. Other revenue for the second quarter of 2009 increased to $10.0 million from $3.8 million in the comparable period last year, primarily due to increased raw material sales.
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1409012/000119312509169181/d10q.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Abraxis Bioscience, Inc..
Abraxis Bioscience, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2009 10-K Annual Report includes:
CIK: 1409012
Form Type: 10-Q Quarterly Report
Accession Number: 0001193125-09-169181
Submitted to the SEC: Fri Aug 07 2009 4:44:27 PM EST
Accepted by the SEC: Fri Aug 07 2009
Period: Tuesday, June 30, 2009
Industry: Pharmaceutical Preparations